[HTML][HTML] Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of K18-hACE2 transgenic mice infected with a …

G Ewart, M Bobardt, BH Bentzen, Y Yan… - PLoS …, 2023 - journals.plos.org
The Coronavirus envelope (E) protein is a small structural protein with ion channel activity
that plays an important role in virus assembly, budding, immunopathogenesis and disease …

[HTML][HTML] Pharmaceutical targeting the envelope protein of SARS-CoV-2: the screening for inhibitors in approved drugs

A Chernyshev - 2020 - europepmc.org
An essential overview of the biological role of coronavirus viroporin (envelope protein) is
given, together with the effect of its known inhibitors on the life cycle of coronavirus. A …

Hepatitis c antiviral compositions and methods

GD Ewart, CA Luscombe, M Miller - US Patent App. 12/670,082, 2010 - Google Patents
0001. This application is a national phase application claiming benefit of priority under 35
USC S371 to Patent Convention Treaty (PCT) International Application Serial No …

Design and Development of NS5B Polymerase Non‐nucleoside Inhibitors for the Treatment of Hepatitis C Virus Infection

PL Beaulieu - 2013 - books.rsc.org
Hepatitis C virus (HCV) infects an estimated 170–200 million people worldwide and is
associated with life-threatening liver diseases such as cirrhosis and hepatocellular …

Solution NMR Structure and Binding Studies of Murine Hepatitis Coronavirus Envelope Protein

B Baravati - 2020 - search.proquest.com
Coronaviruses are the causative agents of SARS, MERS and the ongoing COVID-19
pandemic. Coronavirus envelope proteins have received increasing attention as drug …

COMPOSITION AND USE OF A COMPOSITION

GD Ewart, CA Luscombe, M Miller - 2021 - Google Patents
BR122020008558B1 - COMPOSITION AND USE OF A COMPOSITION - Google Patents
BR122020008558B1 - COMPOSITION AND USE OF A COMPOSITION - Google Patents …

Hepatitis c antiviral compositions and methods

GD Ewart, CA Luscombe, M Miller - US Patent App. 15/638,362, 2017 - Google Patents
US20170362170A1 - Hepatitis c antiviral compositions and methods - Google Patents
US20170362170A1 - Hepatitis c antiviral compositions and methods - Google Patents …

Antiviral compositions for treating hepatitis C based on 5-(1-methylpyrazol-4-yl) 2-naphthoylguanidine and 2'-C-methyladenosine or 2'-C-methylcytidine

GD Ewart, CA Luscombe, M Miller - 2016 - Google Patents
ES2563477T3 - Antiviral compositions for treating hepatitis C based on 5- (1-methylpyrazol-4-yl)
2-naphthoylguanidine and 2'-C-methyladenosine or 2'-C-methylcytidine - Google Patents …

Hepatitis C virus compositions comprising 5-(1-metylpyrazol-4-yl) 2-naphthoylguanidin and 2'-C-metyladenosin or 2'-C-metylcytidin

CA Luscombe, M Miller, GD Ewart - 2016 - Google Patents
PASOFFRBGIVJET-YRKGHMEHSA-N (2R, 3R, 4R, 5R)-2-(6-aminopurin-9-yl)-5-
(hydroxymethyl)-3-methyloxolane-3, 4-diol Chemical compound C [C@@] 1 (O)[C …

Hepatitis c antiviral compositions and methods

GD Ewart, CA Luscombe, M Miller - US Patent App. 14/244,795, 2015 - Google Patents
Publication Classification 514/619; 514/605; 435/375 (51) Int. Cl.(57) ABSTRACT C07C
279/22(2006.01) The present invention relates to novel compositions having A …